22:04 Fri 22 May 2020
ValiRx PLC - Result of General Meeting
("ValiRx", the "Company" or the "Group")
Result of General Meeting and Total Voting Rights
The poll results are set out below:-
Resolutions |
For |
Against |
Discretion |
Resolution 1 (Ordinary) Allotment of share capital
|
1,994,665 |
39,045 |
2,031 |
Resolution 2 (Special) Dis-application of pre-emptive rights
|
1,968,954 |
66,423 |
2,040 |
As a consequence, further to the announcements of
Following admission, the Company will have in issue 36,062,373 ordinary shares with voting rights. The above figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact:
|
Tel: +44 (0) 20 7073 2628 |
|
|
|
Tel: +44 (0) 20 7213 0880 |
|
Tel: +44 (0) 20 7469 0930 |
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.
The Company listed on the AIM Market of the
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE